The FDA enforcement report lists class II recalls, dated 14 October 2026, of compounded semaglutide combined with cyanocobalamin in pre-filled single-use syringes from a US compounding pharmacy. The reason is lack of assurance of sterility, linked to use of bacteriostatic water in the formulation and to processing equipment. The recall is ongoing.
From a pharmacology standpoint, these products combine a peptide with a vitamin in a formulation that has never been tested for stability or sterility as a licensed product. The added cyanocobalamin has no established role alongside semaglutide. Licensed manufacturer pens are not affected.
India does not have an approved compounded incretin route, but patients obtain injectable weight-loss products through informal channels. Ask about the source.
- Ask patients on injectable incretins where they obtain them.
- Treat combination 'semaglutide plus B12' products as unlicensed compounded formulations.
- Consider product contamination when a patient on a compounded injection develops local infection.
- Report suspected contamination to the national pharmacovigilance programme.
Why it matters
Compounded incretin combinations bypass the stability and sterility testing licensed products undergo.
Don't overread it
A sterility-assurance recall is a manufacturing finding, not a report of patient harm.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free